Verastem (NASDAQ:VSTM) Upgraded to Moderate Buy at Royal Bank Of Canada
Verastem (NASDAQ:VSTM – Get Free Report) was upgraded by equities research analysts at Royal Bank Of Canada from an “outperform” rating to a “moderate buy” rating in a research note issued to investors on Wednesday, MarketBeat.com reports. The firm presently has a $12.00 target price on the biopharmaceutical company’s stock, down from their previous target […]
Verastem (NASDAQ:VSTM – Get Free Report) was upgraded by equities research analysts at Royal Bank Of Canada from an “outperform” rating to a “moderate buy” rating in a research note issued to investors on Wednesday, MarketBeat.com reports. The firm presently has a $12.00 target price on the biopharmaceutical company’s stock, down from their previous target […]
